U.S. markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
23.83+1.16 (+5.12%)
At close: 04:00PM EDT
23.42 -0.41 (-1.72%)
After hours: 04:06PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close22.67
Bid23.71 x 3000
Ask23.79 x 900
Day's Range22.90 - 23.89
52 Week Range17.10 - 66.56
Avg. Volume1,371,203
Market Cap2.285B
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-2.44
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est74.55
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for FATE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fate Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/14/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • InvestorPlace

    7 Small-Cap Stocks to Buy Before September Ends

    While broader markets face continued pressure amid recession fears, small-cap stocks stand out as an undervalued segment of the stock market. The Russell 2000 index, the popular benchmark for small-cap stocks, is currently down 18% over the past year. Meanwhile, the S&P 500 index has declined less than 12% during the same period. Seasoned investors realize that a smaller company typically has more room for exponential growth in terms of both business operations and share price. In addition, many

  • Zacks

    Fate Therapeutics (FATE) Down 17% Since Last Earnings Report: Can It Rebound?

    Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    Fate Therapeutics to Participate at Upcoming September Investor Conferences

    SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 2022 in Boston, Massachusetts Hosting 1x1 investor meetings only Wells Far